Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model1
Department of Neurological Surgery, Brain Tumor Research Center (R.S., M.T.K., M.S.B., K.S.B.), and Division of Hematology-Oncology (C.O.N., J.W.P.), University of California, San Francisco, San Francisco, CA 94103; and Hermes Biosciences, Inc., South San Francisco, CA 94080 (D.C.D., D.B.K.); USA
2 Address correspondence to Krystof S. Bankiewicz, Department of Neurological Surgery, University of California at San Francisco, 1855 Folsom Street, Mission Center Building Room 226, San Francisco, CA 94103 (kbank{at}itsa.ucsf.edu).
 |
Abstract |
|---|
Treatment of malignant gliomas represents one of the most formidable challenges in oncology. The combination of surgery, radiation, and chemotherapy yields median survivals of less than one year. Here we demonstrate the use of a minimally invasive surgical technique, convection-enhanced delivery (CED), for local administration of a novel nanoparticle liposome containing topotecan. CED of this liposomal topotecan (Ls-TPT) resulted in extended brain tissue retention (t
= 1.5 days), whereas free topotecan was rapidly cleared (t = 0.1 days) after CED. The favorable pharmacokinetic profile of extended topotecan release for about seven days, along with biodistribution featuring perivascular accumulation of the nanoparticles, provided, in addition to the known topoisomerase I inhibition, an effective antiangiogenic therapy. In the rat intracranial U87MG tumor model, vascular targeting of Ls-TPT with CED was associated with reductions in laminin expression and vascular density compared to free topotecan or control treatments. A single CED treatment on day 7 showed that free topotecan conferred no survival benefit versus control. However, Ls-TPT produced a significant (P = 0.0002) survival benefit, with six of seven complete cures. Larger U87MG tumors, where CED of Ls-TPT on day 12 resulted in one of six cures, indicated the necessity to cover the entire tumor with the infused therapeutic agent. CED of Ls-TPT was also efficacious in the intracranial U251MG tumor model (P = 0.0005 versus control). We conclude that the combination of a novel nanoparticle Ls-TPT and CED administration was very effective in treating experimental brain tumors.
Keywords: antiangiogenesis, brain tumor, convection-enhanced delivery, liposome, topotecan
Received October 28, 2005; Accepted January 6, 2006
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G. Hodgson, R.-F. Yeh, A. Ray, N. J. Wang, I. Smirnov, M. Yu, S. Hariono, J. Silber, H. S. Feiler, J. W. Gray, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts Neuro Oncology, October 1, 2009; 11(5): 477 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Krauze, C. O. Noble, T. Kawaguchi, D. Drummond, D. B. Kirpotin, Y. Yamashita, E. Kullberg, J. Forsayeth, J. W. Park, and K. S. Bankiewicz Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts Neuro Oncology, October 1, 2007; 9(4): 393 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamashita, M. T. Krauze, T. Kawaguchi, C. O. noble, D. C. Drummond, J. W. Park, and K. S. Bankiewicz Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts Neuro Oncology, January 1, 2007; 9(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|